

1 Extravascular spaces are reservoirs of antigenic diversity in 2 *Trypanosoma brucei* infection

3
4 Alexander Beaver^{1,2}, Nathan P. Crilly^{1,2}, Jill Hakim², Bailin Zhang², Bryce Bobb², Filipa Rijo-
5 Ferreira^{3,4}, Luisa Figueiredo⁵, and Monica R. Mugnier^{2*}.

6
7 ¹ Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, United
8 States of America

9
10 ² Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of
11 Public Health, Baltimore, Maryland, United States of America

12
13 ³ Department of Neuroscience, Peter O'Donnell Jr. Brain Institute, University of Texas
14 Southwestern Medical Center, Dallas, Texas, United States of America.

15
16 ⁴ Division of Infectious Diseases and Vaccinology, Berkeley Public Health Molecular and Cell
17 Biology Department, Berkeley, California, United States of America

18
19 ⁵ Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa,
20 Portugal

21
22 * Corresponding author

23 E-mail: mmugnie1@jhu.edu (MRM)

24 25 26 27 **Abstract**

28
29 *Trypanosoma brucei* lives an entirely extracellular life cycle in its mammalian host, facing a
30 constant onslaught of host antibodies. The parasite evades clearance by the host immune
31 system through antigenic variation of its dense variant surface glycoprotein (VSG) coat,
32 periodically “switching” expression of the VSG using a large genomic repertoire of VSG-
33 encoding genes. Studies of antigenic variation *in vivo* have focused exclusively on parasites in
34 the bloodstream, but recent work has shown that many, if not most, parasites are extravascular
35 and reside in the interstitial spaces of tissues. However, it is unknown whether parasites
36 undergo antigenic variation while in extravascular spaces. We sought to explore the dynamics
37 of antigenic variation in extravascular parasite populations using VSG-seq, a high-throughput
38 sequencing approach for profiling VSGs expressed in populations of *T. brucei*. Our experiments
39 show that the expressed VSG repertoire is not uniform across populations of parasites within
40 the same infection and that a greater number of VSGs are expressed in tissue spaces than in
41 the blood. More than 75% of the VSGs detected in an animal were found exclusively within
42 extravascular spaces. Interestingly, we also noticed a delay in the VSG-specific clearance of
43 parasites in tissue spaces compared to the blood. This finding aligns with a model in which
44 parasites “hide” from the immune system in tissue spaces, where a slower immune response
45 provides them with more time to generate new antigenic variants. Overall, our results show that
46 extravascular spaces are significant reservoirs of VSG diversity, potentially resulting from
47 delayed clearance of tissue-resident parasites.

48 Introduction

49
50 *Trypanosoma brucei* is a eukaryotic unicellular parasite and the causative agent of human and
51 animal African Trypanosomiasis¹. Transmitted by the bite of the tsetse fly, it lives extracellularly
52 in the hosts' blood, lymphatic system, interstitial tissue spaces, and central nervous system^{2,3}.
53 Human African trypanosomiasis, a neglected tropical disease, is typically fatal if left untreated.
54 Illness in domestic animals, which can also serve as large parasite reservoirs, results in a
55 significant economic burden to rural Africa^{4,5}.

56
57 *T. brucei* parasites live an entirely extracellular life cycle and face continuous exposure to the
58 host's immune system during infection. To deal with this onslaught of host antibodies, the
59 parasite has evolved a sophisticated mechanism of antigenic variation. *T. brucei* is surrounded
60 by a dense coat of variant surface glycoprotein (VSG). ~10⁷ copies of a single VSG pack onto
61 the parasite's plasma membrane, shielding invariant membrane proteins from immune
62 detection. Though VSG is easily detected by the host immune system⁶, *T. brucei* periodically
63 "switches" expression of the VSG on its surface, using a genomic repertoire of ~2800 different
64 VSG-encoding genes and pseudogenes⁷⁻¹⁰. Parasites expressing these new VSGs are able to
65 avoid immune clearance. In addition to drawing from its large genomic VSG repertoire, *T. brucei*
66 can create novel VSGs using homologous recombination between two or more VSG genes or
67 pseudogenes^{11,12}. These mechanisms give *T. brucei* an enormous capacity for altering its
68 antigenic profile. This arms race between parasites and the host immune system generates
69 waves of parasitemia that are characteristic of *T. brucei* infections¹³.

70
71 Studies examining *T. brucei* antigenic variation *in vivo* have revealed complex dynamics in
72 which populations of parasites express many different VSGs at both peaks and valleys of
73 parasitemia. Indeed, VSG diversity in the blood is much higher than was initially suspected to be
74 required for immune evasion¹⁴⁻¹⁶. It has recently become clear, however, that extravascular
75 spaces represent an important niche for *T. brucei*, in both experimental and natural
76 infections^{17,18}. Within a week post-infection, tissue-resident parasites make up the majority of
77 parasites in a mouse infection¹⁹, and significant reservoirs of parasites have been found in the
78 interstitial areas of nearly every organ^{20,21}. In addition, *T. brucei* parasites within the adipose,
79 skin, and brain have altered gene expression profiles, suggesting an adaptation to their tissue
80 environment^{20,22,23}. Extravascular parasites have also been shown to be associated with
81 increased disease severity¹⁹. While it is clear parasites adapt to extravascular spaces, the
82 precise role of tissue-resident parasites in infection remains unclear, and their contribution to
83 antigenic variation has not been studied.

84
85 Interestingly, parasite tissue tropisms related to antigenic variation have been reported in other
86 organisms. For example in *Plasmodium Falciparum*, expression of a single *var* gene, *var2csa*,
87 allows for parasites to be sequestered in the placenta, aiding in immune evasion and causing
88 severe placental malaria^{24,25}. Similarly, the pili of *Neisseria gonorrhoeae* have critical functions
89 in both antigenic variation and adhesion to host tissue²⁶. In some cases, specific *T. brucei* VSG
90 genes have gained functions besides antigenic variation^{27,28} and VSGs have been shown to
91 potentially influence parasite growth²⁹. It is thus plausible that similar VSG-dependent tropisms
92 exist in *T. brucei* infections, either influencing tissue invasion or adaptation to tissue spaces.

93
94 In this study, we sought to evaluate the role of extravascular parasites in antigenic variation
95 during *T. brucei* infection. We found that blood and tissue-resident parasites express distinct
96 VSG repertoires, even within the same infected mouse, showing that parasite populations in the
97 blood do not fully represent the antigenic complexity of *T. brucei* populations *in vivo*. Moreover,
98 tissue-resident parasites account for most of the antigenic diversity in an infection, serving as a

99 reservoir of new VSGs with the potential to contribute to immune evasion. We also observed a
100 delay in VSG-specific parasite clearance in tissue spaces compared to the blood which could
101 explain the elevated VSG diversity observed in these spaces. Overall, our results demonstrate
102 that tissue-resident *T. brucei* parasites play a distinct role in immune evasion during infection,
103 highlighting the intimate interplay between antigenic variation and the host environment.
104
105

106 **Results**

107

108 **VSG diversification occurs after tissue invasion**

109

110 To investigate the expressed VSG repertoire of *T. brucei* parasites within the blood and tissues
111 of infected mice, we intravenously injected 12 mice with ~5 pleomorphic *T. brucei* EATRO1125
112 AnTat1.1E 90-13 parasites³⁰. We tracked parasitemia in the blood throughout infection (Figure
113 1A) and collected the heart, lungs, gonadal fat, subcutaneous fat, brain, and skin at each of
114 three time points: days 6, 10, and 14. For each mouse, blood was collected on days 6, 10, and
115 14 or until the mouse was sacrificed for tissue collection. Because tissue collection is terminal,
116 each time point is represented by a distinct set of 4 mice. For each sample, we extracted RNA
117 and quantified VSG expression using VSG-Seq. To compare VSG expression between
118 samples, we grouped VSG open reading frames (ORFs) with >98% identity into VSG “clusters.”
119 We then used qPCR to estimate parasite load in each tissue sample and filtered out VSGs that
120 represented less than one parasite (Figure 1B). The number of VSGs in a sample did not
121 correlate with either the number of reads aligned or the number of parasites in a sample
122 (Supplemental Figure 1A & B), suggesting that sampling of each population was sufficient. In
123 total, we identified 1,074 distinct VSGs in all infected mice.

124

125 Our analysis of VSG expression in the blood and tissues revealed that initial populations are
126 quite similar with respect to VSG expression. Because a small inoculum was used, each of
127 these infections was essentially clonal, with a single VSG (either AnTat1.1 or EATRO1125
128 VSG-421) dominating expression in the blood on day 6 post-infection. This “initiating VSG” was
129 also the major population in every tissue space on day 6 (Figure 1C). This early uniformity in
130 VSG expression suggests that in this model of infection *T. brucei* invades tissues before
131 significant VSG switching has occurred.

132

133
134




Figure 1: Extravascular populations diversify independently *in vivo*. (A) Parasitemia of 12 mice infected with AnTat1.1E *T. brucei* counted from tail blood by hemocytometer (n.d. = not detectable). (B) Estimated parasite load per gram from QPCR performed on RNA extracted from perfused and homogenized tissue samples (s.c. fat = subcutaneous fat; gon. fat = gonadal fat). (C) The percent of parasites expressing each VSG within a space. The top 11 VSGs with the highest overall expression are colored and all other VSGs are in grey as “other”. Each row, from the top down, represents mice that were harvested on day 6, 10, and 14, respectively. Day 10 and day 14 mice also have matching blood samples from earlier time points.

135 **VSG clearance is delayed in tissues compared to the blood**

136

137 Because parasite populations in all spaces on day 6 were so similar, we were able to track the
138 clearance of parasites expressing the initiating VSG in blood and tissue spaces. Parasites
139 expressing the initiating VSG were undetectable in every blood sample on day 10 post-infection
140 but remained detectable in 23/24 (~96%) tissue samples. Despite its absence in the blood, the
141 initiating VSG still represented a majority of parasites in some tissue spaces on day 10. By day
142 14, however, parasites expressing the initiating VSG were undetectable in most spaces (Figure
143 2A). Notably, there was no correlation between any specific tissue and the proportion of the
144 population still expressing the initiating VSG.

145

146 To confirm this result from the VSG sequencing data, we performed flow cytometry on parasites
147 from the blood and tissues of mice infected with a tdTomato-expressing “triple reporter” *T.*
148 *brucei* EATRO1125 AnTat 1.1E cell line³¹. These parasites express tdTomato in their cytoplasm
149 and then we stained samples with an anti-AnTat1.1 antibody. We found that in the blood on day
150 13 on average 0.02% of parasites, just above our limit of detection for VSG-seq, expressed
151 AnTat1.1, while on average 1.73% of parasites within the lungs and gonadal fat stained positive
152 for AnTat1.1 (Figure 2B and 2C). These data corroborate measurements by VSG-seq and show
153 that parasites expressing AnTat1.1 persist within tissues after they have been cleared from the
154 blood. As parasites appear to eventually be cleared from tissue spaces, these results are
155 consistent with a model in which the clearance of parasites within extravascular spaces is
156 delayed, but not abolished, compared to the blood.

157




Figure 2: Clearance of parasites expressing the initiating VSG is delayed in tissues compared to the blood. (A) The percent of parasites (log10) expressing the infection initiating VSG (AnTat1.1 or VSG-421) at each time point. Tissue samples were grouped together (blue) and compared to blood samples (red). Statistical significance was determined by a pairwise Wilcoxon test. The horizontal dotted line represents the VSG-seq limit of detection. **(B)** Representative flow cytometry plots from tissues collected from mice infected with chimeric triple marker parasites that express tdTomato constitutively in their cytoplasm. Parasites were stained with anti-AnTat1.1 antibody. The top row shows blood and tissues from one mouse that was collected on day 6 P.I. and the second row shows blood collected from a mouse on both day 6 and day 13 and tissues from day 13 P.I. **(C)** Quantification of the number of parasites that were tdTomato positive and stained positive for AnTat1.1 by flow cytometry (n = 5 per group). The horizontal dotted line marks the limit of detection of VSG-seq.

159 **VSG diversification is not uniform across spaces within a mouse**

160

161 Host humoral immunity and antigenic variation are intrinsically intertwined. As parasites
162 expressing specific VSGs are cleared, other switched parasites persist. We see that as infection
163 progresses and the initiating VSG disappears, VSG expression in populations begins to diverge.
164 On days 10 and 14, the VSG composition of each space is different, and no single VSG
165 dominates. Importantly, VSG expression in the blood no longer matches expression in tissue
166 spaces (Figure 1C). However, we still often see the same VSGs expressed within populations,
167 both within and between infected mice, although in varying compositions. On days 10 and 14,
168 the top eleven most highly expressed VSGs represent an average of 84.07 % and 67.55%,
169 respectively, of parasites in every space. This suggests that the semi-predictable switching
170 hierarchy previously observed within the blood governs antigenic variation in tissue spaces^{14,32}.

171

172 **Tissue-resident parasites account for most of the antigenic diversity in infections**

173

174 The stochasticity of *T. brucei*'s semi-predictable switching hierarchy, however, allows tissue-
175 resident populations to diverge from the blood and from one another. In addition to this
176 frequently expressed subset, populations display a huge diversity of VSGs. At any time, most of
177 the antigenic diversity in an infection is found exclusively within extravascular spaces. In each
178 mouse, 77.19%-94.0% of expressed VSGs were detected exclusively in tissues, while only
179 0.41% to 5.0% of VSGs are found exclusively within the blood (Figure 3A and 3B). Individual
180 tissue spaces generally harbor more VSGs than the blood as well (Figure 3C). Given the large
181 number of VSGs unique to these spaces, we sought to address whether certain VSGs were
182 more likely to emerge in certain tissue microenvironments. Notably, we found no evidence for
183 tissue-specific VSGs or VSG sequence motifs (Supplemental Figure 2).

184

185 Central to antigenic variation is the expression of new VSGs to which the host immune system
186 has not yet been exposed. To evaluate the potential for tissue-resident parasite populations to
187 generate new variants, and thus facilitate immune evasion, we examined the proportion of
188 VSGs expressed in each space that are only found within that space in a mouse. We termed
189 these "unique" VSGs (Figure 4A). Day 6 samples were excluded from this analysis because
190 very few VSGs are expressed at this time point. Between 4.8% to 35.5% of VSGs within any
191 space are unique to that space. Tissue spaces generally display a greater proportion of unique
192 VSGs than the blood (Figure 4B), though these unique VSGs typically represent a relatively
193 small proportion of the total parasite population in each space (Figure 4C). Taken together
194 these results suggest that tissue-resident populations are diversifying independently and that
195 blood-resident parasites alone do not reflect the complexity of antigenic variation *in vivo*. There
196 is the potential capacity for parasites in every space to contribute new antigenic variants to an
197 infection.

198




Figure 3: Populations of extravascular parasites harbor most of the antigenic diversity in an infection. (A) Stacked bar graphs from each mouse representing the proportion of VSGs that were found exclusively within the blood (red), exclusively within tissue spaces (blue), or shared by both the blood and at least one tissue space (green). **(B)** Quantification of the number of VSGs found within the blood (red) or tissue spaces (blue) at each timepoint. Each point represents a blood or tissue sample from a mouse. Statistical significance was determined by a Student's t-test between the blood and tissues within each timepoint. **(C)** The number of VSGs represented in each tissue space (for each tissue and day 14 blood; n= 4, for day 6 blood n = 12, for day 10 blood n =8). A pairwise Dunnett's test was performed between all spaces within each timepoint.




Figure 4: Tissue-resident parasites have the potential to contribute unique VSGs to an infection. (A) We define “unique” VSGs as those VSGs solely found within a specific space in a mouse (Created with BioRender.com). **(B)** The percent of VSGs that were unique to one space within a mouse (n = 4 per group). Statistical significance was determined using a pairwise Dunnett’s test. **(C)** The percentage of each population represented by unique VSGs.

200

201

202 **VSGs initially only seen in tissues can be found in all spaces later during infection**

203

204 Tissue spaces harbor many VSGs unique to the extravascular niche, but many of these are
 205 expressed by a small number of parasites. We sought to understand whether these rare VSGs
 206 exclusive to tissues had the potential to establish within other spaces in the host, suggesting a
 207 role in immune evasion, or if they simply represented dead ends for the parasite. To address
 208 this question, we identified VSGs only expressed in tissues on day 6 post-infection and
 209 analyzed their fates at later timepoints, specifically looking to see if they appeared later within
 210 the blood. Of these 58 VSGs only in tissues on day 6, 43 (74.1%) were expressed on day 10 or
 211 day 14 within the blood. By examining a few of these VSGs more closely, we saw that VSG
 212 cluster 294, which was initially only expressed in tissues on day 6, represented a large
 213 proportion of parasites on day 10, particularly within the blood. Interestingly, we also observed
 214 the same delayed clearance of VSG cluster 294 within extravascular spaces as we had
 215 previously seen with the initiating VSG. VSG clusters 504 and 1831 also represented small
 216 populations of parasites in tissues on day 6, but later become highly expressed in both the
 217 blood and tissue spaces (Figure 5). Thus, rare VSGs expressed at low levels exclusively in
 218 tissue spaces have the potential to become ubiquitously expressed within a host, raising
 219 interesting questions about the ability for tissue parasites to reseed the blood, aiding in immune
 220 evasion.




Figure 5: VSGs only seen in tissues on day 6 are often seen in the blood and tissues later during infections. The expression (log₁₀) of VSG cluster 294, 504, and 1831 within all samples on days 6, 10, and 14. Samples were grouped into two groups, blood (red) or tissues (blue).

221 Discussion

222
223 Previous *in vivo* studies of antigenic variation in *T. brucei* have investigated the phenomenon
224 solely in blood-resident parasite populations^{12,14,15}. Recent work, however, has revealed that
225 large numbers of parasites reside in extravascular spaces outside of the bloodstream^{3,17,20}. Here
226 we show that the majority of the antigenic diversity during infection is found exclusively within
227 these tissue-resident populations of *T. brucei* parasites. Moreover, individual extravascular
228 parasite populations often express more VSGs than populations in the blood. VSGs detected at
229 low levels in tissues at early time points post-infection can become highly expressed VSGs
230 within the blood at later time points, suggesting these extravascular reservoirs of antigenic
231 diversity could be vital for parasite immune evasion and disease chronicity.

232
233 The renewed interest in tissue-resident *T. brucei* parasites has generated speculation about the
234 possibility that VSGs could play a role in tissue tropism for *T. brucei*. Interestingly, we saw no
235 evidence of tissue-specific VSG expression in these experiments. Because parasites invade
236 tissues efficiently before significant VSG switching has occurred, it appears unlikely that any
237 specific VSG is required for tissue invasion. Whether some VSGs may provide an adaptation to
238 specific host spaces is less clear. We only measured VSG expression up to day 14 post-
239 infection, at which point tissue-resident populations were just beginning to diverge from one
240 another and the blood. It is therefore possible that, as these populations further evolve, there
241 may be selection for VSGs better adapted to certain tissue spaces. It is also possible that a
242 relationship between VSG expression and tissue tropism could emerge in an infection initiated
243 by a tsetse bite, where the inoculum is larger³⁶ and likely more antigenically diverse.

244
245 Instead of tissue-specific VSG expression, our data support a model in which each tissue-
246 resident population is evolving independently, influenced by the same semi-predictable
247 switching hierarchy that has been seen to govern VSG expression in the blood^{14,37}.
248 Nevertheless, the scale of antigenic variation in these spaces is quite different. The number of
249 VSGs we detected in the blood corroborates previous estimates^{12,14,15}, but the diversity in tissue
250 spaces is, on average, two to four times higher than the blood. Overall, tissue-resident
251 populations harbor ~95% of the antigenic diversity in any given infection.

252
253 It is unclear what mechanisms or circumstances lead to the increased diversity we observe in
254 extravascular spaces. Why do tissue spaces harbor so many more VSGs? One intriguing
255 possibility is that parasites in tissue spaces are actually switching at a higher rate than those in

256 the blood. The mechanisms that initiate VSG switching during infection remain poorly
257 understood. While DNA double-strand breaks can trigger VSG switching *in vitro*^{38,39}, it remains
258 unclear whether they serve as a natural trigger for switching *in vivo*. It is plausible to speculate
259 that some aspect of the extravascular environment could supply a molecular or physical
260 stimulus that promotes VSG switching, leading to increased VSG diversity within these spaces.
261

262 A second, and not mutually exclusive, explanation for the increased antigenic diversity in tissue
263 spaces lies in the observation that VSG-specific clearance of parasites is delayed in
264 extravascular spaces. By day 10 post-infection, parasites expressing the initiating VSG are
265 undetectable in the blood but remain in tissue spaces until at least day 14. Perhaps parasites
266 within these spaces, which survive longer before being cleared, simply have more opportunity to
267 switch. An increased survival time would allow extravascular populations to accumulate many
268 more switched parasites over time, resulting in the higher VSG diversity we observe. Thus,
269 extravascular spaces could serve as a haven for diversification and a reservoir of antigenic
270 diversity to seed the blood.
271

272 This increased diversity could be vital in natural infections, particularly in wild animals, where
273 pre-existing anti-VSG immunity is more likely to exist. In this case, a high rate of switching may
274 be required to successfully evade the host's existing anti-VSG antibody repertoire. For
275 extravascular populations to impact systemic antigenic variation, however, extravascular
276 parasites must be able to exit tissue spaces and enter the blood. Vascular permeability is high
277 after the initial stages of infection¹⁹, suggesting parasites likely move back and forth between
278 spaces, but this has not yet been definitively demonstrated. It will thus be critical to demonstrate
279 that parasites can move from tissue spaces to the blood. Nevertheless, our data are consistent
280 with a model in which variants generated in tissues later seed the blood: rare variants detected
281 exclusively within tissue spaces on day 6 post-infection can be detected at high levels in the
282 blood at later timepoints.
283

284 While the immune response in extravascular spaces is clearly distinct from the blood, the nature
285 of the immune response in these spaces that leads to a delay in VSG-specific parasite
286 clearance is unknown. Perhaps surprisingly, our data suggest the mechanism is not organ-
287 specific. Instead, delayed clearance and increased antigenic diversity appear to be general
288 features of extravascular infection. This fact points to one possible explanation for the delay we
289 observe. IgM, a bulky pentamer, is the first antibody to respond to infection and initiates around
290 day 6 with a peak around day 10 post-infection in mice. IgG, on the other hand, is a monomer
291 that peaks around day 14 post-infection^{40,41}. There is some evidence that IgM cannot diffuse
292 into tissue spaces adequately^{42,43}. If anti-VSG IgM diffuses poorly into extravascular spaces,
293 then extravascular parasites would not be fully cleared until IgG is produced. We observe
294 clearance in extravascular spaces that coincides with peak serum levels of IgG, supporting this
295 model. Of course, it is also possible that local extravascular immune responses mount with
296 different dynamics than the systemic response. Whatever the mechanism, it is apparent that
297 extravascular spaces are distinct from the blood in multiple ways.
298

299 Our experiments demonstrate that extravascular spaces serve as important reservoirs of VSG
300 during *T. brucei* infection, accounting for the vast majority of antigenic diversity in any individual
301 infection. Our data suggest that this could be due, in part, to a delayed immune response in
302 extravascular spaces that allows parasites to survive longer and switch more. This study raises
303 compelling questions about the nature of extravascular immunity, initiation of VSG switching *in*
304 *vivo*, and the process of reseeding parasites into the blood. Overall, our results establish
305 extravascular spaces as an important and previously overlooked niche for antigenic variation in
306 *T. brucei*.

307 **Methods**

308

309 **Mouse infections and sample collection**

310

311 12 female C57Bl/6J (Jackson Laboratory) between 7-10 weeks old were each infected
312 by intravenous tail vein injection with ~5 pleiomorphic EATRO 1125 AnTat1.1E 90-13 *T. brucei*
313 parasites³⁰. Blood parasitemia was counted by tail bleed every 2 days starting on day 4 post-
314 infection (PI) by hemocytometer. Blood (25uL) was collected by a submandibular bleed on days
315 6, 10, and 14 PI and placed into TRIzol LS. Four Mice were anesthetized and perfused at each
316 time point (days 6, 10, and 14 PI). Mice were perfused with 50mL of PBS-Glucose (0.055M D-
317 glucose) with heparin. After perfusion, tissues were dissected and placed immediately into 1mL
318 of RNA later. The heart, lungs, gonadal fat, subcutaneous fat, brain, and skin (ear) were
319 collected.

320 For flow cytometry experiments, 7-10 week old female C57Bl/6J mice were infected by
321 intravenous tail vein injection with ~5 AnTat1.1E chimeric triple reporter *T. brucei* parasites
322 which express tdTomato³¹. Blood was collected by a submandibular bleed at each time point.
323 Mice were anesthetized and perfused on days 6 and 13 P.I. as discussed above and the
324 gonadal fat and lungs were harvested.

325

326 **VSG-seq sample and library preparation**

327

328 RNA was isolated from blood samples stored in TRIzol LS (ThermoFisher, 10296010) by
329 phenol/chloroform extraction. Tissue samples were weighed and homogenized in TRIzol, and
330 then RNA was isolated by phenol/chloroform extraction. RNA from each sample was DNase
331 treated using Turbo DNase and cleaned up with Mag-Bind® TotalPure NGS beads (Omega Bio-
332 Tek

333 M1378-00). First-strand cDNA synthesis was performed using SuperScript III Reverse
334 Transcriptase and a primer that binds to the conserved VSG 14-mer in the 3'-UTR (5'-
335 GTGTTAAAATATATC-3'). Products were cleaned up using Mag-Bind® TotalPure NGS beads
336 (Omega Bio-Tek, M1378-01). Next, a VSG-specific PCR with Phusion polymerase
337 (ThermoFisher, F530L) was performed using primers for the spliced leader (5'-
338 ACAGTTTCTGTACTATATTG-3') and SP6-VSG 14-mer sequences (5'-
339 GATTTAGGTGACACTATAGTGTTAAAATATATC-3') for 25 cycles. VSG-PCR products were
340 cleaned up using Mag-Bind® TotalPure NGS beads and quantified using the QuBit HS DNA kit
341 (Life Technologies). Finally, sequencing libraries were prepared with the Nextera XT DNA
342 Sample Prep Kit (Illumina) using the manufacturer's guidelines, and libraries were sequenced
343 with 100bp single-end reads on an Illumina HiSeq 2500.

344

345 **Tissue QPCR**

346

347 First-strand synthesis was performed with SuperScript III Reverse Transcriptase
348 (Thermo Fisher Scientific, 18080051) and random hexamers primers on tissue RNA samples.
349 QPCR was performed in triplicate using SYBR Green qPCR Master Mix (Invitrogen, 4309155).
350 ZFP3 primers were used to estimate parasite load in tissue samples (FW: 5'-
351 CAGGGGAAACGCAAACTAA-3'; RV: 5'-TGTCACCCCAACTGCATTCT-3'). CT values were
352 averaged between the triplicates and parasite load per mg of tissue were estimated using a
353 standard curve of values from RNA isolated from known numbers of cultured parasites.

354

355

356

357

358 **VSG-seq analysis**

359

360 Analysis of sequencing results was performed following the method we reported
361 previously¹⁴, with two changes: no mismatches were allowed for bowtie alignments and each
362 sample was analyzed (assembly, alignment, and quantification) separately. To compare
363 expressed VSG sets between samples, all assembled VSGs were clustered using CD-HIT-
364 EST⁴⁴, with VSGs with >98% identity grouped into clusters. VSGs were then identified by their
365 Cluster number for further analysis. Samples that had less than 100,000 successfully aligning
366 reads to VSGs were excluded from further analysis. Four samples, 3 brain and 1 heart, were
367 discarded because fewer than 100,000 reads aligned to VSG (Supplemental Figure 1A).

368 Downstream analysis of expression data and generation of figures was performed in R. Code
369 for generating the analysis and figures in this paper are available at

370 <https://github.com/mugnierlab/Beaver2022>.

371

372 **Analysis of VSG sequence motifs**

373

374 To identify tissue-specific VSGs, the similarity of N terminal sequences from all
375 assembled VSGs were compared. N terminal sequences were identified using a HMMER scan
376 against a database curated by Cross et al. Then all N termini were compared in an all vs all
377 blast using default parameters. All VSG pairwise comparisons with an e-value higher than 1E-3
378 were considered sufficiently similar to one another for further analysis. VSGs that were found in
379 a given tissue were binned into that tissue group, and the distribution of the bitscores in a given
380 compartment was compared against the total population of similar VSGs.

381

382 **Flow Cytometry**

383

384 Once mice were perfused, tissues were dissected and washed with HBSS (Hanks
385 balanced salt solution, ThermoFisher Scientific 14175095). Tissue samples were minced and
386 placed in DMEM (ThermoFisher Scientific, 11995065) containing either 1 mg/mL collagenase
387 type 1 (ThermoFisher Scientific, 17100017) for adipose fat or 2 mg/mL collagenase type 2
388 (ThermoFisher Scientific, 17101015) for lung samples. These were then incubated in a 37°C
389 water bath for 1 hour and briefly vortexed every 10 minutes. Next, samples were passed
390 through a 70µM filter and centrifuged at 2600 x g for 8 mins at 4 C, and the cell pellet was taken
391 for antibody staining.

392 Blood samples were collected by submandibular bleed and red blood cells were
393 depleted by magnetic-activated cell sorting (MACS) with anti-Ter-119 MicroBeads (Miltenyi
394 Biotech, 130-049-901) following the manufacturer's protocol. Cells were pelleted and washed
395 with HMI-9 media.

396 All samples, both blood and tissues, were stained with Zombie Aqua™ dye at 1:100 in
397 PBS and washed with PBS following the manufacturer's protocol (BioLegend, 423101).
398 Samples were then stained for 10 minutes at 4°C with a rabbit anti-AnTat1.1 polyclonal antibody
399 diluted 1:15,000 in HMI-9 media and washed once with HMI-9 (antibody courtesy of Jay Bangs).
400 Then, secondary antibody staining was performed for 10 minutes at 4°C with Anti-Rabbit IgG
401 conjugated to Alexa Fluor® 488 fluorescent dye (Cell Signaling Technology, 4412S). Finally,
402 samples were washed with cold PBS and resuspended in PBS for flow cytometry analysis.
403 Samples were run on a Beckton Dickinson A3 Symphony flow cytometer and analysis was
404 performed using FlowJo (version 10.6.1).

405

406

407

408

409 **Acknowledgments**

410
411 We would like to kindly thank Jay Bangs for supplying us with the anti-AnTat1.1 antibody and
412 Brice Rotureau for providing us with the chimeric triple reporter cell line. We thank Tricia Nilles
413 and Worod Allak at the Becton Dickinson Immunology and Flow Cytometry core at Johns
414 Hopkins Bloomberg School of Public Health for training, support, and technical assistance using
415 the BD FACS Symphony A3. The facility is supported in part by CFAR: 5P30AI094189-04
416 (Chaisson). Data analysis was carried out at the Advanced Research Computing at Hopkins
417 (ARCH) core facility (rockfish.jhu.edu), which is supported by the National Science Foundation
418 (NSF) grant number OAC 1920103. AB was supported by NIH T32AI007417. NC was
419 supported by NIH T32 OD011089. FR-F is supported by NIH NIGMS 1K99GM132557-01 and is
420 an Investigator in the Chan Zuckerberg Biohub. MRM, AB, BB, and BZ were supported by
421 Office of the Director, NIH (DP5OD023065).

422
423 **References**


- 424
425 1. WHO. Control and surveillance of human African trypanosomiasis: Report of a WHO
426 Expert Committee. *WHO Tech Rep Ser.* 2013;(984):1-237.
427 [https://www.proquest.com/scholarly-journals/control-surveillance-human-](https://www.proquest.com/scholarly-journals/control-surveillance-human-african/docview/1504252667/se-2?accountid=11752)
428 [african/docview/1504252667/se-2?accountid=11752.](https://www.proquest.com/scholarly-journals/control-surveillance-human-african/docview/1504252667/se-2?accountid=11752)
- 429 2. Dumas M, Bouteille B, Buguet A. *Progress in Human African Trypanosomiasis, Sleeping*
430 *Sickness.*; 2013.
431 [https://books.google.com/books?hl=en&lr=&id=zL_zBwAAQBAJ&oi=fnd&pg=PA1&ots=ni](https://books.google.com/books?hl=en&lr=&id=zL_zBwAAQBAJ&oi=fnd&pg=PA1&ots=ni_8fjcZp-&sig=NfOo7IBHyt_z3EnRIk7S99tBCOk)
432 [_8fjcZp-&sig=NfOo7IBHyt_z3EnRIk7S99tBCOk.](https://books.google.com/books?hl=en&lr=&id=zL_zBwAAQBAJ&oi=fnd&pg=PA1&ots=ni_8fjcZp-&sig=NfOo7IBHyt_z3EnRIk7S99tBCOk) Accessed April 29, 2022.
- 433 3. Crilly NP, Mugnier MR. Thinking outside the blood: Perspectives on tissue-resident
434 *Trypanosoma brucei*. *PLOS Pathog.* 2021;17(9):e1009866.
435 doi:10.1371/JOURNAL.PPAT.1009866
- 436 4. Kennedy PGE, Rodgers J. Clinical and neuropathogenetic aspects of human African
437 trypanosomiasis. *Front Immunol.* 2019;10(JAN). doi:10.3389/fimmu.2019.00039
- 438 5. WHO. Trypanosomiasis, human African (sleeping sickness) Fact sheet.
439 [https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-](https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness))
440 [\(sleeping-sickness\).](https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)) Published 2022. Accessed April 29, 2022.
- 441 6. Magez S, Schwegmann A, Atkinson R, et al. The Role of B-cells and IgM Antibodies in
442 Parasitemia, Anemia, and VSG Switching in *Trypanosoma brucei*-Infected Mice. Black S,
443 ed. *PLoS Pathog.* 2008;4(8):e1000122. doi:10.1371/journal.ppat.1000122
- 444 7. Cross GAM, Kim H-S, Wickstead B. Capturing the variant surface glycoprotein repertoire
445 (the VSGnome) of *Trypanosoma brucei* Lister 427. *Mol Biochem Parasitol.*
446 2014;195(1):59-73. doi:10.1016/j.molbiopara.2014.06.004
- 447 8. Hertz-Fowler C, Figueiredo LM, Quail MA, et al. Telomeric Expression Sites Are Highly
448 Conserved in *Trypanosoma brucei*. Hall N, ed. *PLoS One.* 2008;3(10):e3527.
449 doi:10.1371/journal.pone.0003527
- 450 9. Müller LSM, Cosentino RO, Förstner KU, et al. Genome organization and DNA
451 accessibility control antigenic variation in trypanosomes. *Nature.* 2018;563(7729):121-
452 125.
- 453 10. Cosentino R, Brink B, Siegel T. A phased genome assembly for allele-specific analysis in
454 *Trypanosoma brucei*. *bioRxiv.* April 2021:2021.04.13.439624.
455 doi:10.1101/2021.04.13.439624

- 456 11. Kamper SM, Barbet AF. Surface epitope variation via mosaic gene formation is potential
457 key to long-term survival of *Trypanosoma brucei*. *Mol Biochem Parasitol*. 1992;53(1-
458 2):33-44.
459 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1380125)
460 [Plus&list_uids=1380125](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1380125).
- 461 12. Hall JPJ, Wang H, Barry JD. Mosaic VSGs and the scale of *Trypanosoma brucei*
462 antigenic variation. Horn D, ed. *PLoS Pathog*. 2013;9(7):e1003502.
463 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=23853603)
464 [Plus&list_uids=23853603](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=23853603).
- 465 13. A case of sleeping sickness studied by precise enumerative methods: Regular periodical
466 increase of the parasites disclosed. *Proc R Soc London Ser B, Contain Pap a Biol*
467 *Character*. 1910;82(557):411-415. doi:10.1098/RSPB.1910.0035
- 468 14. Mugnier MR, Cross GAM, Papavasiliou FN. The in vivo dynamics of antigenic variation in
469 *Trypanosoma brucei*. *Science (80-)*. 2015;347(6229):1470-1473.
470 doi:10.1126/science.aaa4502
- 471 15. Jayaraman S, Harris C, Paxton E, et al. Application of long read sequencing to determine
472 expressed antigen diversity in *Trypanosoma brucei* infections. Acosta-Serrano A, ed.
473 *PLoS Negl Trop Dis*. 2019;13(4):e0007262. doi:10.1371/journal.pntd.0007262
- 474 16. Hall JPJ, Wang H, David Barry J. Mosaic VSGs and the Scale of *Trypanosoma brucei*
475 Antigenic Variation. *PLoS Pathog*. 2013;9(7). doi:10.1371/JOURNAL.PPAT.1003502
- 476 17. Capewell P, Cren-Travaillé C, Marchesi F, et al. The skin is a significant but overlooked
477 anatomical reservoir for vector-borne African trypanosomes . *Elife*. 2016;5:157.
478 <https://elifesciences.org/articles/17716>.
- 479 18. Camara M, Soumah AM, Ilboudo H, et al. Extravascular Dermal Trypanosomes in
480 Suspected and Confirmed Cases of gambiense Human African Trypanosomiasis. *Clin*
481 *Infect Dis*. 2021;73(1):12-20. doi:10.1093/cid/ciaa897
- 482 19. De Niz M, Brás D, Ouarné M, et al. Organotypic endothelial adhesion molecules are key
483 for *Trypanosoma brucei* tropism and virulence. *Cell Rep*. 2021;36(12):109741.
484 doi:10.1016/J.CELREP.2021.109741
- 485 20. Trindade S, Rijo-Ferreira F, Carvalho T, et al. *Trypanosoma brucei* Parasites Occupy and
486 Functionally Adapt to the Adipose Tissue in Mice. *Cell Host Microbe*. 2016;19(6):837-848.
487 doi:10.1016/j.chom.2016.05.002
- 488 21. Carvalho T, Trindade S, Pimenta S, Santos AB, Rijo-Ferreira F, Figueiredo LM.
489 *Trypanosoma brucei* triggers a marked immune response in male reproductive organs.
490 *PLoS Negl Trop Dis*. 2018;12(8). doi:10.1371/journal.pntd.0006690
- 491 22. Quintana JF, Chandrasegaran P, Sinton MC, et al. Integrative single cell and spatial
492 transcriptomic analysis reveal reciprocal microglia-plasma cell crosstalk in the mouse
493 brain during chronic *Trypanosoma brucei* infection. *bioRxiv*. March
494 2022:2022.03.25.485502. doi:10.1101/2022.03.25.485502
- 495 23. Reuter C, Imdahl F, Hauf L, et al. Vector-borne *Trypanosoma brucei* parasites develop in
496 artificial human skin and persist as skin tissue forms. *bioRxiv*. May
497 2021:2021.05.13.443986. doi:10.1101/2021.05.13.443986
- 498 24. Salanti A, Dahlbäck M, Turner L, et al. Evidence for the Involvement of VAR2CSA in
499 Pregnancy-associated Malaria. *J Exp Med*. 2004;200(9):1197-1203.
500 doi:10.1084/JEM.20041579


- 501 25. Duffy PE, Fried M. Plasmodium falciparum adhesion in the placenta. *Curr Opin Microbiol.*
502 2003;6(4):371-376. doi:10.1016/S1369-5274(03)00090-0
- 503 26. Jonsson A -B, Ilver D, Falk P, Pepose J, Normark S. Sequence changes in the pilus
504 subunit lead to tropism variation of Neisseria gonorrhoeae to human tissue. *Mol*
505 *Microbiol.* 1994;13(3):403-416. doi:10.1111/J.1365-2958.1994.TB00435.X
- 506 27. Silva Pereira S, Jackson AP, Figueiredo LM. Evolution of the variant surface glycoprotein
507 family in African trypanosomes. *Trends Parasitol.* 2022;38(1):23-36.
508 doi:10.1016/J.PT.2021.07.012
- 509 28. Wiedemar N, Graf FE, Zwyer M, et al. Beyond immune escape: a variant surface
510 glycoprotein causes suramin resistance in Trypanosoma brucei. *Mol Microbiol.*
511 2018;107(1):57-67. doi:10.1111/MML.13854
- 512 29. Liu D, Albergante L, Newman TJ, Horn D. Faster growth with shorter antigens can
513 explain a VSG hierarchy during African trypanosome infections: a feint attack by
514 parasites. *Sci Rep.* 2018;8(1):10922. doi:10.1038/s41598-018-29296-8
- 515 30. Engstler M, Boshart M. Cold shock and regulation of surface protein trafficking convey
516 sensitization to inducers of stage differentiation in Trypanosoma brucei. *Genes Dev.*
517 2004;18(22):2798. doi:10.1101/GAD.323404
- 518 31. Calvo-Alvarez E, Cren-Travaillé C, Crouzols A, Rotureau B. A new chimeric triple reporter
519 fusion protein as a tool for in vitro and in vivo multimodal imaging to monitor the
520 development of African trypanosomes and Leishmania parasites. *Infect Genet Evol.*
521 2018;63:391-403. doi:10.1016/J.MEEGID.2018.01.011
- 522 32. Morrison LJ, Majiwa P, Read AF, Barry JD. Probabilistic order in antigenic variation of
523 Trypanosoma brucei. *Int J Parasitol.* 2005;35(9):961-972.
524 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16000200)
525 [Plus&list_uids=16000200.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16000200)
- 526 33. Zeelen J, Straaten M van, Verdi J, et al. Structure of Trypanosome Coat Protein VSGsur
527 and Function in Suramin Resistance. *Nat Microbiol.* 2021;6(3):392. doi:10.1038/S41564-
528 020-00844-1
- 529 34. So J, Sudlow S, Sayeed A, et al. Trypanosomal variant surface glycoprotein expression
530 in human African trypanosomiasis patients. *bioRxiv.* September
531 2021:2021.09.09.459620. doi:10.1101/2021.09.09.459620
- 532 35. Cadavid D, Pennington PM, Kerentseva TA, Bergström S, Barbour AG. Immunologic and
533 genetic analyses of VmpA of a neurotropic strain of Borrelia turicatae. *Infect Immun.*
534 1997;65(8):3352. doi:10.1128/IAI.65.8.3352-3360.1997
- 535 36. Caljon G, van Reet N, De Trez C, Vermeersch M, Pérez-Morga D, Van Den Abbeele J.
536 The Dermis as a Delivery Site of Trypanosoma brucei for Tsetse Flies. Peters NC, ed.
537 *PLoS Pathog.* 2016;12(7):e1005744. [http://dx.plos.org/10.1371/journal.ppat.1005744.](http://dx.plos.org/10.1371/journal.ppat.1005744)
- 538 37. Morrison L, Majiwa P, Read A, for JB-I journal, 2005 undefined. Probabilistic order in
539 antigenic variation of Trypanosoma brucei. *Elsevier.*
540 <https://www.sciencedirect.com/science/article/pii/S0020751905001712>. Accessed April
541 29, 2022.
- 542 38. Glover L, Alford S, Horn D. DNA Break Site at Fragile Subtelomeres Determines
543 Probability and Mechanism of Antigenic Variation in African Trypanosomes. *PLoS*
544 *Pathog.* 2013;9(3):1003260. doi:10.1371/journal.ppat.1003260
- 545 39. Boothroyd CE, Dreesen O, Leonova T, et al. A yeast-endonuclease-generated DNA

- 546 break induces antigenic switching in *Trypanosoma brucei*. *Nature*. 2009;459(7244):278-
547 281. doi:10.1038/nature07982
- 548 40. Magez S, Schwegmann A, Atkinson R, et al. The role of B-cells and IgM antibodies in
549 parasitemia, anemia, and VSG switching in *Trypanosoma brucei*-infected mice. *PLoS*
550 *Pathog*. 2008;4(8):e1000122.
551 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=18688274)
552 [Plus&list_uids=18688274](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=18688274).
- 553 41. Schopf LR, Filutowicz H, Bi X-J, Mansfield JM. Trypanosome Variant Surface
554 Glycoprotein Antigen-Specific Th1-Cell Response to the Isotype Switch in the Presence
555 of a Polarized Interleukin-4-Dependent Immunoglobulin G1. *Infect Immun*.
556 1998;66(2):451. <http://iai.asm.org/content/66/2/451>
557 [http://iai.asm.org/content/66/2/451#ref-](http://iai.asm.org/content/66/2/451#ref-list-1)
list-1. Accessed January 4, 2019.
- 558 42. Hector RF, Collins MS, Pennington JE. Treatment of Experimental *Pseudomonas*
559 *aeruginosa* Pneumonia with a Human IgM Monoclonal Antibody. *J Infect Dis*.
560 1989;160(3):483-489. doi:10.1093/INFDIS/160.3.483
- 561 43. BARTH WF, WOCHNER RD, WALDMANN TA, FAHEY JL. Metabolism of Human
562 Gamma Macroglobulins. *J Clin Invest*. 1964;43(6):1036. doi:10.1172/JCI104987
- 563 44. Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation
564 sequencing data. *Bioinformatics*. 2012;28(23):3150.
565 doi:10.1093/BIOINFORMATICS/BTS565
- 566
567
568
569
570
571
572
573
574
575
576
577
578
579




580 Supplemental Figures




Supplemental Figure 1: VSG diversity counts are not biased by the sample's read count or parasite count. (A) A comparison of the number of reads successfully aligned in a sample and the number of VSGs found. **(B)** A comparison of the total number of parasites and the number of VSGs found in each sample.




Supplemental Figure 2: No tissue-specific VSGs or VSG sequence motifs exist. Distribution of bitscores across tissue compartments. The similarity of VSGs extracted from each tissue as measured by bitscore, a sequence similarity metric normalized to the database size, allows for comparing tissue compartments with different numbers of total VSGs expressed in each tissue. No statistical significance was found.

A**B****C**


A







C




B






A**B**




Percent of VSGs unique to only one space within each mouse

**C**

Percent of the population represented by VSGs unique to that space



Log10(Percent of parasites
expressing the labeled VSG)





Time post infection (days)

Space


- blood
- tissues

Tissue


- blood
- brain
- ear
- gon
- heart
- lung
- sub

A**B**


All tissues




brain bitscore




skin bitscore




gon. fat bitscore




heart bitscore



lung bitscore



s.c. fat bitscore



blood bitscore

